While its specialty pharmacy business is offsetting some of the weakness, the PBM segment is tracking slightly below previous expectations. The brokerage noted Cigna delivered a solid second quarter, reporting adjusted EPS of $7.78, topping consensus by $0.18, helped by stronger-than-expected performances at both Cigna Healthcare and Evernorth. Management modestly raised its 2026 adjusted EPS guidance to at least $30.45 from $30.35, while maintaining its medical loss ratio outlook. The firm continues to model 2026 adjusted EPS of $30.50, followed by $33.50 in 2027 and $37.00 in 2028. Related articlesRaymond James cuts Cigna to Outperform on lack of near-term catalystsThese 2 stocks are best positioned to benefit from higher uranium prices: analystAs Claude disrupts stock market, Anthropic researcher warns 'world is in peril'